TELA Bio, Inc. (TELA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 18 | 29 | 41 | 58 | 69 | 80 | 80 | 80 |
| Operating profit | $m | -34 | -34 | ||||||
| Net profit | $m | -29 | -33 | -44 | -47 | -38 | -39 | -41 | -32 |
| EPS reported | $ | -0.83 | -0.77 | ||||||
| Operating cashflow per share | $ | -0.60 | -0.52 | ||||||
| Capex per share | $ | 0.01 | 0.01 | ||||||
| FCF per share | $ | -0.61 | -0.53 | ||||||
| Free cash flow | $m | -29 | -32 | ||||||
| Net debt | $m | 5 | 26 | ||||||
| Book value equity | $m | 6 | -16 | ||||||
| Book value per share | $ | 0.13 | -0.28 | ||||||
| Number of shares | m | 46.95 | 57.41 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 8.78 | -3.49 | ||||||
| P/S LTM | x | 0.69 | 0.69 | ||||||
| P/FCF LTM | x | -1.93 | -1.75 | ||||||
| EV/EBITDA LTM | x | -1.86 | -1.82 | ||||||
| EV/Sales LTM | x | 0.75 | 0.72 | ||||||
| Earnings Yield LTM | % | -70.09% | -74.82% | ||||||
| FCF Yield | % | -51.75% | -57.08% | ||||||
| Quality | |||||||||
| ROE | % | -615.10% | -1344.5% | ||||||
| ROIC | % | -53.21% | -64.29% | ||||||
| Operating margin | % | -42.05% | -41.84% | ||||||
| Gross margin | % | +67.69% | +67.25% | ||||||
| FCF/Sales | % | -35.71% | -37.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +15.84% | +15.31% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.52 | -0.56 | ||||||
| Net Debt/EBITDA | x | -0.15 | -0.52 | ||||||
| EBIT/Net interest | x | -6.44 | -17.14 | ||||||
| Net debt/market cap | % | +1.00% | +1.36% | ||||||
| Net debt/Equity | x | 0.76 | -1.65 | ||||||
| Gross debt/equity | x | 8.82 | -3.57 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free